サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1635964

男性性腺機能低下症市場レポート：治療タイプ別、ドラッグデリバリー別、用途別、地域別、2025-2033年

Male Hypogonadism Market Report by Therapy Type, Drug Delivery, Application, and Region 2025-2033

出版日
発行
IMARC
ページ情報
英文 134 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
男性性腺機能低下症市場レポート：治療タイプ別、ドラッグデリバリー別、用途別、地域別、2025-2033年
出版日: 2025年01月10日
発行: IMARC
ページ情報: 英文 134 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

男性性腺機能低下症の市場の世界市場規模は2024年に39億米ドルに達しました。今後、IMARC Groupは、市場は2033年までに58億米ドルに達し、2025年から2033年にかけて4.31%の成長率（CAGR）を示すと予測しています。男性におけるテストステロン欠乏症の有病率の大幅な上昇、患者集団における男性性腺機能低下症治療の選択肢に対する意識の高まり、健康意識の高まりが市場を牽引する主な要因のいくつかです。

男性性腺機能低下症は、精巣が十分なテストステロンを産生できず、筋肉の成長の欠如、毛髪の成長障害、乳房の開発、声の深みの欠如などを引き起こす病状です。この病状の特徴は、男性におけるテストステロンまたは精子の産生不足です。精巣（原発性性腺機能低下症）または視床下部-下垂体軸（続発性腺機能低下症）に関連する障害によって引き起こされます。性腺機能低下症は、視床下部と下垂体に影響を及ぼす精巣の問題や障害に起因するため、さまざまな臓器の機能障害だけでなく、生活の質の低下に悩まされる可能性があります。男性における性腺機能低下症は、遺伝的なものと後天的なものがあり、ホルモンバランスの乱れ、薬物、加齢などによって引き起こされます。いくつかの先天性酵素異常は、全身にさまざまな程度のアンドロゲン抵抗性を引き起こす原因となっています。性腺機能低下症は、60歳以上の男性に最も多くみられ、それに応じて症状や欠乏の兆候も異なります。

男性性腺機能低下症の市場傾向：

世界市場は主に、男性におけるテストステロン欠乏症の有病率の大幅な上昇と不妊率の増加によって牽引されています。この背景には、肥満や糖尿病などの慢性的な生活習慣病の増加があります。これに伴い、男性性腺機能低下症を開発しやすい老年人口の拡大も市場に刺激を与えています。さらに、患者集団の間で男性性腺機能低下症治療の選択肢に対する認識が高まっていることも、重要な成長促進要因として作用しています。いくつかの国の政府機関は、テストステロン補充療法（TST）を含む性腺機能低下症治療法の認知を促進しています。しかし、テストステロンホルモンの外部注射に伴う重篤な副作用は、男性性腺機能低下症の市場の重要な成長抑制因子として作用しています。逆に、臨床試験の増加や新たな治療オプションの出現は、予測期間中に新たな男性性腺機能低下症の市場の成長機会を生み出すと予想されます。これとは別に、世界レベルでの医療インフラ開発における継続的な技術進歩が、市場に明るい見通しを生み出しています。その他の市場開拓要因としては、急速な都市化、健康意識の高まり、高額医療費、広範な研究開発活動などが挙げられます。

本レポートで扱う主な質問

  • 世界の男性性腺機能低下症の市場はこれまでどのように推移し、今後どのように推移していくのか？
  • 世界の男性性腺機能低下症の市場における促進要因、抑制要因、機会は何か？
  • 主要地域市場とは？
  • 最も魅力的な男性性腺機能低下症市場はどの国か？
  • 治療タイプ別の市場内訳は？
  • ドラッグデリバリーに基づく市場内訳は？
  • 用途別の市場内訳は？
  • 世界の男性性腺機能低下症の市場の競合構造は？
  • 世界の男性性腺機能低下症の市場における主要プレイヤー/企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要業界動向

第5章 世界の男性性腺機能低下症市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：治療タイプ別

  • テストステロン補充療法
    • 市場動向
    • 市場予測
  • ゴナドトロピン放出ホルモン療法
    • 市場動向
    • 市場予測

第7章 市場内訳：ドラッグデリバリー別

  • 外用ジェル
    • 市場動向
    • 市場予測
  • 注射剤
    • 市場動向
    • 市場予測
  • 経皮パッチ
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第8章 市場内訳：用途別

  • カルマン症候群
    • 市場動向
    • 市場予測
  • クラインフェルター症候群
    • 市場動向
    • 市場予測
  • 下垂体疾患
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第9章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋地域
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ

第10章 促進要因・抑制要因・機会

  • 概要
  • 促進要因
  • 抑制要因
  • 機会

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第13章 価格分析

第14章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • AbbVie Inc
    • Endo International Plc
    • Ferring Holding S.A
    • Grunenthal GmbH
    • Lilly USA, LLC（Eli Lilly and Company）
    • Pfizer Inc
    • Sun Pharmaceutical Industries Limited
    • Teva Pharmaceutical Industries Ltd
図表

List of Figures

  • Figure 1: Global: Male Hypogonadism Market: Major Drivers and Challenges
  • Figure 2: Global: Male Hypogonadism Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Male Hypogonadism Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Male Hypogonadism Market: Breakup by Therapy Type (in %), 2024
  • Figure 5: Global: Male Hypogonadism Market: Breakup by Drug Delivery (in %), 2024
  • Figure 6: Global: Male Hypogonadism Market: Breakup by Application (in %), 2024
  • Figure 7: Global: Male Hypogonadism Market: Breakup by Region (in %), 2024
  • Figure 8: Global: Male Hypogonadism (Testosterone Replacement Therapy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 9: Global: Male Hypogonadism (Testosterone Replacement Therapy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 10: Global: Male Hypogonadism (Gonadotropin-Releasing Hormones Therapy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 11: Global: Male Hypogonadism (Gonadotropin-Releasing Hormones Therapy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 12: Global: Male Hypogonadism (Topical Gels) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 13: Global: Male Hypogonadism (Topical Gels) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 14: Global: Male Hypogonadism (Injectables) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: Global: Male Hypogonadism (Injectables) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: Global: Male Hypogonadism (Transdermal Patches) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: Global: Male Hypogonadism (Transdermal Patches) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Global: Male Hypogonadism (Other Drug Deliveries) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 19: Global: Male Hypogonadism (Other Drug Deliveries) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 20: Global: Male Hypogonadism (Kallmann Syndrome) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Global: Male Hypogonadism (Kallmann Syndrome) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: Global: Male Hypogonadism (Klinefelters Syndrome) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: Global: Male Hypogonadism (Klinefelters Syndrome) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: Global: Male Hypogonadism (Pituitary Disorders) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 25: Global: Male Hypogonadism (Pituitary Disorders) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 26: Global: Male Hypogonadism (Other Applications) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 27: Global: Male Hypogonadism (Other Applications) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 28: North America: Male Hypogonadism Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 29: North America: Male Hypogonadism Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 30: United States: Male Hypogonadism Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 31: United States: Male Hypogonadism Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 32: Canada: Male Hypogonadism Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 33: Canada: Male Hypogonadism Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 34: Asia-Pacific: Male Hypogonadism Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 35: Asia-Pacific: Male Hypogonadism Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 36: China: Male Hypogonadism Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 37: China: Male Hypogonadism Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: Japan: Male Hypogonadism Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 39: Japan: Male Hypogonadism Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 40: India: Male Hypogonadism Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 41: India: Male Hypogonadism Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 42: South Korea: Male Hypogonadism Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 43: South Korea: Male Hypogonadism Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 44: Australia: Male Hypogonadism Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 45: Australia: Male Hypogonadism Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 46: Indonesia: Male Hypogonadism Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 47: Indonesia: Male Hypogonadism Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 48: Others: Male Hypogonadism Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 49: Others: Male Hypogonadism Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 50: Europe: Male Hypogonadism Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 51: Europe: Male Hypogonadism Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 52: Germany: Male Hypogonadism Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 53: Germany: Male Hypogonadism Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 54: France: Male Hypogonadism Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 55: France: Male Hypogonadism Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 56: United Kingdom: Male Hypogonadism Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 57: United Kingdom: Male Hypogonadism Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 58: Italy: Male Hypogonadism Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 59: Italy: Male Hypogonadism Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 60: Spain: Male Hypogonadism Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 61: Spain: Male Hypogonadism Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 62: Russia: Male Hypogonadism Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 63: Russia: Male Hypogonadism Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 64: Others: Male Hypogonadism Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 65: Others: Male Hypogonadism Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 66: Latin America: Male Hypogonadism Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 67: Latin America: Male Hypogonadism Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 68: Brazil: Male Hypogonadism Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 69: Brazil: Male Hypogonadism Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 70: Mexico: Male Hypogonadism Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 71: Mexico: Male Hypogonadism Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 72: Others: Male Hypogonadism Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 73: Others: Male Hypogonadism Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 74: Middle East and Africa: Male Hypogonadism Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 75: Middle East and Africa: Male Hypogonadism Market: Breakup by Country (in %), 2024
  • Figure 76: Middle East and Africa: Male Hypogonadism Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 77: Global: Male Hypogonadism Industry: Drivers, Restraints, and Opportunities
  • Figure 78: Global: Male Hypogonadism Industry: Value Chain Analysis
  • Figure 79: Global: Male Hypogonadism Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Male Hypogonadism Market: Key Industry Highlights, 2024 & 2033
  • Table 2: Global: Male Hypogonadism Market Forecast: Breakup by Therapy Type (in Million USD), 2025-2033
  • Table 3: Global: Male Hypogonadism Market Forecast: Breakup by Drug Delivery (in Million USD), 2025-2033
  • Table 4: Global: Male Hypogonadism Market Forecast: Breakup by Application (in Million USD), 2025-2033
  • Table 5: Global: Male Hypogonadism Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 6: Global: Male Hypogonadism Market: Competitive Structure
  • Table 7: Global: Male Hypogonadism Market: Key Players
目次
Product Code: SR112024A7206

The global male hypogonadism market size reached USD 3.9 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 5.8 Billion by 2033, exhibiting a growth rate (CAGR) of 4.31% during 2025-2033. A considerable rise in the prevalence of testosterone deficiency in males, the rising awareness of male hypogonadism treatment choices among the patient population, and increasing health consciousness represent some of the key factors driving the market.

Male hypogonadism is a medical condition in which the testes fail to produce enough testosterone, leading to a lack of muscle growth, impaired hair growth, breast development, as well as a lack of deepening of the voice. The medical condition is characterized by a lack of testosterone or spermatozoa production in men. It is caused owing to the disorder related to the testes (primary hypogonadism) or the hypothalamic-pituitary axis (secondary hypogonadism). An individual with hypogonadism may suffer from a variety of organ dysfunctions as well as a reduction in quality of life since it originates from a testicular problem or disorder that affects the hypothalamus and pituitary gland. Hypogonadism in men can be genetic or acquired, caused by hormonal imbalances, medications or aging. Several congenital enzyme abnormalities are responsible for causing different degrees of androgen resistance throughout the body. Hypogonadism is most common in men over the age of 60, and the symptoms and indications of the deficiency vary accordingly.

Male Hypogonadism Market Trends:

The global market is primarily driven by a considerable rise in the prevalence of testosterone deficiency in males, along with the growing infertility rates. This can be attributed to the increasing incidences of chronic lifestyle disorders, including obesity and diabetes. In line with this, the expanding geriatric population that is more susceptible to developing male hypogonadism is also providing an impetus to the market. Moreover, the rising awareness of male hypogonadism treatment choices among the patient population is also acting as a significant growth-inducing factor. Government bodies across several countries are promoting awareness of hypogonadism treatment methods, including testosterone replacement therapy (TST). However, severe adverse reactions associated with external testosterone hormone injections are acting as a significant growth-restraining factor for the male hypogonadism market. Conversely, the increasing number of clinical trials and the emergence of new treatment options are expected to create new male hypogonadism market opportunities for growth during the forecast period. Apart from this, continual technological advancements in the development of medical infrastructure on the global level are creating a positive outlook for the market. Some of the other factors contributing to the market include rapid urbanization, increasing health consciousness, high medical expenditure and extensive research and development (R&D) activities.

Key Market Segmentation:

Therapy Type Insights

Testosterone Replacement Therapy

Gonadotropin-Releasing Hormones Therapy

Drug Delivery Insights

Topical Gels

Injectables

Transdermal Patches

Others

Application Insights

Kallmann Syndrome

Klinefelters Syndrome

Pituitary Disorders

Others

Regional Insights

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and Middle East and Africa. According to the report, North America was the largest market for male hypogonadism. Some of the factors driving the North America male hypogonadism market include the growing geriatric population, rising prevalence of sedentary lifestyle and related medical conditions, increasing number of clinical trials, the emergence of new treatment options, etc.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global male hypogonadism market. Detailed profiles of all major companies have also been provided. Some of the companies covered include AbbVie Inc, Endo International Plc, Ferring Holding S.A, Grunenthal GmbH, Lilly USA, LLC (Eli Lilly and Company), Pfizer Inc, Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd, etc.

Key Questions Answered in This Report:

  • How has the global male hypogonadism market performed so far and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global male hypogonadism market?
  • What are the key regional markets?
  • Which countries represent the most attractive male hypogonadism markets?
  • What is the breakup of the market based on the therapy type?
  • What is the breakup of the market based on the drug delivery?
  • What is the breakup of the market based on the application?
  • What is the competitive structure of the global male hypogonadism market?
  • Who are the key players/companies in the global male hypogonadism market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Male Hypogonadism Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Therapy Type

  • 6.1 Testosterone Replacement Therapy
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Gonadotropin-Releasing Hormones Therapy
    • 6.2.1 Market Trends
    • 6.2.3 Market Forecast

7 Market Breakup by Drug Delivery

  • 7.1 Topical Gels
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Injectables
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Transdermal Patches
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Application

  • 8.1 Kallmann Syndrome
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Klinefelters Syndrome
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Pituitary Disorders
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

  • 10.1 Overview
  • 10.2 Drivers
  • 10.3 Restraints
  • 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 AbbVie Inc
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Endo International Plc
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Ferring Holding S.A
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
    • 14.3.4 Grunenthal GmbH
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 SWOT Analysis
    • 14.3.5 Lilly USA, LLC (Eli Lilly and Company)
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
    • 14.3.6 Pfizer Inc
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Sun Pharmaceutical Industries Limited
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Teva Pharmaceutical Industries Ltd
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.